3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
4
Dermatologic
3
Sarcoma
2
Genitourinary
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Recurrence
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
bempegaldesleukin
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts